Skip to content
PubMed This is a summary of 45 peer-reviewed journal articles Updated
Metabolic Medicine

Homocystinuria due to methylene tetrahydrofolate reductase deficiency: A Patient Guide

At a Glance

Severe MTHFR deficiency is a rare inherited disorder that causes homocysteine to build up and methionine to fall. Early treatment with betaine, specialized folate, and B vitamins, plus regular metabolic monitoring, can reduce health risks but may not reverse established injury.

Homocystinuria due to severe MTHFR deficiency is a rare, inherited metabolic disorder that impairs the folate and sulfur-amino-acid pathways. It is a remethylation disorder, meaning the body lacks the functioning enzyme needed to recycle a substance called homocysteine back into an essential building block called methionine [1]. Because this recycling process is broken, homocysteine levels in the blood can rise to dangerously high levels while methionine levels often drop too low. This biochemical imbalance is the hallmark of the disease and serves as the primary target for all medical treatments [2].

It is vital to distinguish this rare condition from the common genetic variations, or polymorphisms, frequently discussed in online wellness communities. While many people carry minor variations in the MTHFR gene that may slightly influence how they process folate, severe MTHFR deficiency is an autosomal recessive disease [3]. This means a person has inherited pathogenic variants in both copies of the gene—one from each parent—resulting in an enzyme that has severely reduced or no activity. This is not a common variation; it is a serious medical condition that requires lifelong care from a metabolic specialist [4][5].

The condition generally presents in two ways, though the severity and age of onset can vary widely and are not perfectly predictable based solely on genetics. In the most severe infantile-onset cases, babies may show signs within weeks or months of birth, including feeding difficulties, seizures, or pauses in breathing [6]. In late-onset cases, symptoms may not emerge until childhood or even adulthood, often appearing as changes in walking, cognitive function, mood, or as unexplained blood clots [7]. While early treatment reduces risk, it cannot guarantee normal development or completely reverse established injury.

Living with severe MTHFR deficiency involves a highly individualized “treatment regimen” designed to bypass the impaired enzyme. The core of this treatment is betaine, a medication that provides an alternative path for the body to clear homocysteine [2]. Along with specialized forms of folate (like 5-MTHF or folinic acid) and other B-vitamins, this treatment works to restore chemical balance. Consistent treatment and close monitoring by a dedicated care team are the most powerful tools available to support long-term health and stability [5][8].

Common questions in this guide

What is homocystinuria caused by severe MTHFR deficiency?
It is a rare inherited metabolic disorder in which the body cannot efficiently recycle homocysteine into methionine because the MTHFR enzyme has little or no activity. Homocysteine can become very high and methionine can become low. This is different from common MTHFR gene variations discussed online.
How is severe MTHFR deficiency inherited and confirmed?
The condition follows an autosomal recessive pattern, so a person has pathogenic variants in both copies of the MTHFR gene, one inherited from each parent. A metabolic specialist considers genetic results together with the characteristic blood pattern of high homocysteine and often low methionine. Common MTHFR gene variations do not establish this diagnosis.
What symptoms can severe MTHFR deficiency cause?
Severe cases may begin in infancy with feeding difficulties, seizures, or pauses in breathing. Later-onset disease may cause changes in walking, thinking, mood, or unexplained blood clots during childhood or adulthood. The age and severity of symptoms can vary widely.
How is MTHFR deficiency homocystinuria treated?
Betaine is the core treatment because it provides another route for lowering homocysteine. Doctors may also prescribe specialized folate, such as 5-MTHF or folinic acid, along with other B vitamins. The regimen is individualized and requires regular monitoring of homocysteine and methionine.
What do homocysteine and methionine levels mean in this condition?
High homocysteine and low methionine reflect the blocked recycling process caused by severe MTHFR deficiency. These blood levels help the care team judge whether treatment is restoring the desired chemical balance. Your metabolic specialist can set target ranges and decide how often to test.
Can early treatment prevent long-term problems?
Starting treatment early can reduce health risks, but it cannot guarantee normal development or completely reverse injury that has already occurred. Consistent betaine, folate, and vitamin treatment with close monitoring supports long-term stability. The care team should tailor expectations to the person's age, symptoms, and response.
What should patients and families monitor day to day?
Patients and families should follow the prescribed daily betaine, folate, and vitamin routine and keep scheduled blood tests. Ask the metabolic team for a plan for illness or missed doses, and discuss physical and cognitive milestones after diagnosis. Do not change or stop treatment without clinical guidance.

Get notified when new evidence is published on Homocystinuria due to methylene tetrahydrofolate reductase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Methylene Tetrahydrofolate Reductase Deficiency.

    Kaur R, Correa ARE, Thakur S, et al.

    Indian journal of pediatrics 2020; (87(11)):951-953 doi:10.1007/s12098-020-03290-3.

    PMID: 32451826
  2. 2

    First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders.

    Olivieri G, Bordugo A, Burnyte B, et al.

    Journal of inherited metabolic disease 2026; (49(4)):e70177 doi:10.1002/jimd.70177.

    PMID: 42231716
  3. 3

    MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature.

    Levin BL, Varga E

    Journal of genetic counseling 2016; (25(5)):901-11 doi:10.1007/s10897-016-9956-7.

    PMID: 27130656
  4. 4

    Manifestations of neurological symptoms and thromboembolism in adults with MTHFR-deficiency.

    Rommer PS, Zschocke J, Fowler B, et al.

    Journal of the neurological sciences 2017; (383()):123-127 doi:10.1016/j.jns.2017.10.035.

    PMID: 29246599
  5. 5

    Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency.

    Huemer M, Diodato D, Schwahn B, et al.

    Journal of inherited metabolic disease 2017; (40(1)):21-48 doi:10.1007/s10545-016-9991-4.

    PMID: 27905001
  6. 6

    Influence of early identification and therapy on long-term outcomes in early-onset MTHFR deficiency.

    Yverneau M, Leroux S, Imbard A, et al.

    Journal of inherited metabolic disease 2022; (45(4)):848-861 doi:10.1002/jimd.12504.

    PMID: 35460084
  7. 7

    Clinical and molecular characterization of adult patients with late-onset MTHFR deficiency.

    Marelli C, Lavigne C, Stepien KM, et al.

    Journal of inherited metabolic disease 2021; (44(3)):777-786 doi:10.1002/jimd.12323.

    PMID: 33089527
  8. 8

    Clinical pattern, mutations and in vitro residual activity in 33 patients with severe 5, 10 methylenetetrahydrofolate reductase (MTHFR) deficiency.

    Huemer M, Mulder-Bleile R, Burda P, et al.

    Journal of inherited metabolic disease 2016; (39(1)):115-24 doi:10.1007/s10545-015-9860-6.

    PMID: 26025547

This page is for informational purposes only and does not constitute medical advice about severe MTHFR deficiency. Your metabolic specialist and care team should guide diagnosis, treatment, and monitoring.